Weight-based combination therapy with peginterferon alpha-2b and ribavirin for Naïve, relapser and non-responder patients with chronic hepatitis C

Weight-based combination therapy with peginterferon alpha-2b and ribavirin for Naïve, relapser and non-responder patients with chronic hepatitis C

Autor Gonçales Junior, Fernando Lopes Google Scholar
Vigani, Aline Google Scholar
Gonçales, Neiva Google Scholar
Barone, Antonio Alci Google Scholar
Araújo, Evaldo Google Scholar
Focaccia, Roberto Google Scholar
Oliveira, Umbeliana Google Scholar
Coelho, Henrique Sérgio Morais Google Scholar
Paixao, Jacqueline Google Scholar
Perez, Renata de Mello Autor UNIFESP Google Scholar
Lobato, Cirley Google Scholar
Weirich, Judith Google Scholar
Rosa, Heitor Google Scholar
Borges, Andrelina Google Scholar
Vila, Ricardo Google Scholar
Corrêa-Giannella, Maria Lúcia Google Scholar
Ferraz, Maria Lucia Cardoso Gomes Autor UNIFESP Google Scholar
Instituição Faculty of Medical Sciences of Campinas
São Paulo University School of Medicine
Emilio Ribas Institute
Federal University of Rio de Janeiro
Universidade Federal de São Paulo (UNIFESP)
Secretary of Health of Acre
Federal University of Goiás
Schering-Plough Brazil
São Paulo University Medical School Laboratory of Medical Investigations
Resumo Combination therapy with pegylated interferon and ribavirin is considered the new standard therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment with weight-based peginterferon alpha-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48 weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin) patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was 54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was significantly higher in patients with the non-1 genotype (67%) compared to those with genotype 1 (45%). In relapsers and non-responders, SVR was, respectively, 69% and 24% in patients with genotype 1 and 43% and 73% in those with genotype non-1. There were no significant differences in SVR rates among the three body weight ranges (< 65 kg, 65-85 kg and > 85 kg) in any of the subgroups. Early virological response (EVR) was reached by 78%, 81% and 58% of naïve, relapser and non-responder patients, respectively, and among those with EVR, 63%, 67% and 61%, respectively, subsequently achieved SVR. All of the non-responder patients who did not have EVR reached SVR. Treatment was discontinued in 13% of the patients, due to loss to follow-up, hematological abnormalities or depression.
Palavra-chave Hepatitis C
interferon alpha-2b
therapy
Idioma Inglês
Data de publicação 2006-10-01
Publicado em Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 10, n. 5, p. 311-316, 2006.
ISSN 1413-8670 (Sherpa/Romeo)
Publicador Brazilian Society of Infectious Diseases
Extensão 311-316
Fonte http://dx.doi.org/10.1590/S1413-86702006000500002
Direito de acesso Acesso aberto Open Access
Tipo Artigo
SciELO S1413-86702006000500002 (estatísticas na SciELO)
Endereço permanente http://repositorio.unifesp.br/handle/11600/3292

Exibir registro completo




Arquivo

Nome: S1413-86702006000500002.pdf
Tamanho: 64.85KB
Formato: PDF
Descrição:
Abrir arquivo

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta